CORTISPORIN (hydrocortisone; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1975.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
CORTISPORIN is a fixed-dose combination otic solution containing hydrocortisone (corticosteroid), neomycin sulfate (aminoglycoside antibiotic), and polymyxin B sulfate (polypeptide antibiotic). It treats superficial bacterial infections of the external auditory canal caused by susceptible organisms including Staphylococcus aureus and gram-negative bacteria. The triple-agent mechanism combines anti-inflammatory activity with dual bactericidal coverage to address infection and inflammation simultaneously.
As a near-LOE product in a mature, niche otic indication, brand teams face revenue decline and reduced headcount; opportunities lie in defending market share against generics and leveraging established commercial infrastructure.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CORTISPORIN in a LOE-approaching environment offers limited career growth; roles focus on defensive market share tactics, managed decline, and generic transition strategy. This is typically a shorter-tenure assignment suited to early-career professionals seeking operational efficiency experience or experienced personnel managing portfolio runoff.